Here, we have interrogated datasets from the TCGA database publicly available to better understand the role of BECN1 and BRCA1 deficiency in progression and chemo-responsiveness to platinum-based therapy in wild-type and mutated TP53 ovarian cancers. The gene discussed is BRCA1; the disease is ovarian cancer.